NCT01265875

Secretin Infusion for Pain Due to Chronic Pancreatitis

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: ChiRhoClin, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

* To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion. * To validate the safety of intravenous secretin administration at the dosage indicated in this study.

Detailed description

12 patients will be enrolled in this study. Patients will be only those treated at Dartmouth-Hitchcock Medical Center for the diagnosis of CP. The diagnosis of CP will be made by the PI based on standard clinical, radiographic and/or biochemical criteria. Patients must be taking prescribed opioid analgesics for the specific treatment of CP at the time of study enrollment. Only patients between the ages of 18-70 and capable of providing informed consent will be considered eligible for the study.

Conditions

• Chronic Pancreatitis

Interventions

Type	Name	Description
DRUG	Human Secretin	Dose Escalation

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-12-01
• Completion: 2012-04-01
• First posted: 2010-12-23
• Last updated: 2016-03-09
• Results posted: 2016-03-01

Locations

1 site across 1 country: United States